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Rare cancers in The Netherlands: a population-based study
Jan M. van der Zwana, Boukje A.C. van Dijka,b, Otto Vissera,
Han J.H.J.M. van Kriekenc, Riccardo Capocacciae and Sabine Sieslinga,d
The conventional definition for rare disease is based on
prevalence. Because of differences in prognosis, a definition
on the basis of incidence was deemed to be more
appropriate for rare cancers. Within the European
RARECARE project, a definition was introduced that defines
cancers as rare when the crude incidence rate is less than
six per 100 000 per year. In this study, we applied the
RARECARE definition for rare cancer to the Netherlands;
this to identify the usefulness of the definition in a single
country and to provide more insight into the burden of rare
cancers in the Netherlands. Data for 2004 through 2008
were extracted from the Netherlands Cancer Registry and
classified according to the RARECARE entities (tumour
groupings). Crude and European standardized incidence
rates were calculated. Out of the 260 entities, 223 (86%)
were rare according to the definition, accounting for 14 000
cancers (17% of all). Considerable fluctuations in crude
rates over years were observed for the major group of
cancers. Rare tumours in the Netherlands constituted 17%
of all newly diagnosed tumours, but were divided over 223
different entities, indicating the challenge that faces
clinicians. To make the definition of rare cancers better
applicable, it should be refined by taking into consideration
the sex-specific incidence for sex-specific cancer sites.
Moreover, a mean incidence over 5 years will provide more
solid insight into the burden, eliminating large fluctuations
in time of most of the cancers. European Journal of Cancer
Prevention 27:384–390 Copyright © 2018 Wolters Kluwer
Health, Inc. All rights reserved.
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Introduction
Clinicians consider patients with rare cancers in most
cases as a challenge because they do not encounter a
patient with this specific type of cancer regularly and are
therefore less experienced with diagnostics, staging and
treatment.
Until recently, only a definition for rare diseases on the
basis of the prevalence rate existed. Diseases are defined
as rare when the prevalence is less than 50 per 100 000 in
the community (European Parliament and Council of the
European Communities, 2003). Moreover, the American
Orphan Drug Act defines rare diseases as those affecting
fewer than 200 000 individuals in the USA (Developing
Products for Rare Diseases & Conditions, 2011). For
cancer, however, using prevalence as a measure of rarity
may not be the most suitable. Some cancers with a low
incidence but a good survival will have a high prevalence
and would therefore not be considered rare. Still, the low
incidence means limited opportunities to become
acquainted with the specifics of diagnosis and treatment.
Therefore, in the RARECARE project, a new definition
was developed defining rare cancers, which was based on
a wide consensus among organizations representing
medical professionals (surgeons, pathologists and medical
oncologists). Cancer should be considered rare when the
crude incidence rate is less than six per 100 000 per year
(Gatta et al., 2010, 2011).
The RARECARE project provided a list of rare cancers
for Europe and not for the separate European countries
(Gatta et al., 2010). Applying the definition to a single
country will provide information on the usefulness of the
definition on a national level. Furthermore, knowledge of
the burden of rare cancers for a specific country could
give an impulse in awareness and might lead to the
development of (inter)national guidelines supporting the
clinicians in diagnoses and treatment decision making.
Moreover, the discussion on (virtual) centralizing the care
for these patients within a country or even between
countries could be supported; concentration of knowl-
edge by increasing volume will identify caveats and
tackle gaps of knowledge related to the management of
patients with rare forms of cancer. It can also give an
impulse to research focusing on diagnosis and treatment
for this diverse group of patients in relation to outcome.
In this paper, we applied the RARECARE definition for
rare cancer to the Netherlands for 2004 to 2008 to iden-
tify the usefulness of and to quantify rare cancers on a
national level to provide more insight into the burden of
rare cancers in the Netherlands.
All supplementary digital content is available directly from the corresponding
author.
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Methods
Study population
In this study, data from the population-based
Netherlands Cancer Registry (NCR) were included.
The NCR covers the complete Dutch population and
receives lists of newly diagnosed cancer cases from the
nationwide Automated Pathology System (PALGA) on a
weekly basis (Casparie et al., 2007). In addition, lists of
discharged cancer patients from the national registry of
hospital discharge diagnosis are obtained to capture
cancer cases with only a clinical diagnosis (About Cancer
Registry, 2011). Completeness checks showed a national
coverage of about 95% of incident cancers (Goldbohm
et al., 1994).
A high level of data quality is secured by the specially
trained registry clerks who abstract patient, tumour and
treatment characteristics directly from the patient files.
International standards set by the International
Association for Cancer Registries and the European
Network of Cancer Registries are used (Curado et al.,
2007). The International Classification of Disease for
Oncology, 3rd ed. (ICD-O-3) developed by the WHO is
used. To study fluctuations in incidence over several
years, we selected data over the period 2004–2008, cov-
ering a 5-year period. The period 2004–2008 was selected
as this period had the most complete data at the time of
data inclusion.
Tumour grouping
The RARECARE project performed a data selection
using the EUROCARE 4 database. The RARECARE
data collection was carried out following the
EUROCARE protocol and using the RARECARE
inclusion criteria; this enables the working group to
standardize and obtain data checks for analyses (De
Angelis et al., 2009; Gatta et al., 2011). The RARECARE
project linked their newly developed definition to a
predefined list of cancers that follows a three-layer
structure of cancer type groupings (entities), including
all existing ICD-O-3 topography and malignant mor-
phology codes (Fritz et al., 2000). Layer one entities are
considered family of cancers relevant for healthcare
organizations, created by grouping layer two entities.
Layer two entities are defined in a clinically sound
manner (perceived by clinicians as single diseases and
relevant for clinical decision making and research) and
are based on the third layer that corresponds to the WHO
names of individual cancer entities and their corre-
sponding ICD-O-3 codes. The definition for rare and
common cancer entities only applies to the first two
levels, with a total of 260 cancer types in Europe (59 first
layers/201 second layers).
For this study, we classified all cancers according to the
RARECARE list (http://www.rarecare.eu) (Gatta et al.,
2010).Ep
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Methods of analysis
The number of newly diagnosed cancers was counted per
year per entity for the selected period. Annual incidence
rates were calculated per 100 000 person years using the
annual mid-year population size obtained from Statistics
Netherlands (CBS).
Furthermore, the European standardized rate (ESR) was
computed by correcting the crude incidence rate for sex
and age using the European standardized population. For
the sex-specific cancer entities, we calculated the crude
incidence and ESR using the sex-specific population at
risk. For all rates, the mean for the 5-year period was
determined. All outcomes were compared with the
RARECARE results as presented on their website (http://
www.rarecare.eu).
Results
In the Netherlands, 86% of the RARECARE-defined
entities and 17% (N≈ 14 000) of all newly diagnosed
cancers should be considered rare according to the
RARECARE definition.
Out of the total 260 entities defined by RARECARE, we
identified 223 entities (86%) with a crude incidence rate
of less than 6.0 per 100 000 per year in the Netherlands
over 5 years (Appendix). ‘Squamous cell of the cervix
uteri’ and the ‘tumours of the testis and paratestis’ were
considered rare in Europe, but common in the
Netherlands, whereas ‘Tumours of the liver and intra-
hepatic bile tract’ and the ‘epithelial tumours of the
hypopharynx and larynx’ were rare cancers in the
Netherlands, but common in Europe. The 223 rare
entities included 42 rare first-layer cancer entities
(Table 1) and 181 second layer entities. Of these second
layer entities, 54 (incidence rate< 6.0 per 100 000 person
years per year) were included in 15 nonrare first-layer
entities (incidence rate ≥ 6.0 per 100 000 per year)
(Table 2). An example is the rare second-layer entity
‘epithelial tumour of the male breast’, which is included
in the not rare first-layer entity ‘epithelial tumour of the
breast’.
In the years 2004–2008 combined, more than 71 000
patients were newly diagnosed with a rare cancer type.
On an average, the crude number resulted in 14 279 rare
cancers (range 13 421–15 108) per year out of a total of
84 479 cancers (range 80 616–89 228) per year in the
Netherlands (Table 3).
Table 4 shows that for the period 2004–2008, the group
with an annual incidence rate of up to 0.5 per 100 000
comprised an estimated number of 881 cases per year,
representing 6.2% of all rare cancers. This group of very
rare cancers consists of a relatively large number of
entities (N= 85). Of these, 54 entities were rare second-
layer entities within nonrare first-layer entities, repre-
senting 23.9% of all rare tumours and 4.0% of all cancers.
The annual crude incidence rate was generally very low
for these entities, with the exception of squamous cell
carcinoma and variants of the ‘Oesophagus’ and ‘Germ
cell seminomatous tumours of the testis’ (crude incidence
rate> 3 per 100 000 per year) (Table 2).
We observed fluctuations in incidence rates for many
cancer types through the years 2004–2008 for some first-
layer entities. The difference in crude rate was 0.9 per
100 000 (149 cases) for ‘Myeloproliferative neoplasms’
between 2004 and 2007 (Table 1). However, the largest
difference in ESR between the highest and the lowest
count was 0.9 per 100 000 per year for the ‘Epithelial
tumour of the hypopharynx and larynx’, accounting for an
absolute difference of 124 cancer cases between 2005 and
2007 (Table 1). Fluctuations in incidence over the years
also showed that the cut-off of less than six per 100 000
per year could be crossed during the time period. An
example is the entity ‘Adenocarcinoma and variants of
the oesophagus’, for which a crude incidence rate of 5.4
per 100 000 per year was calculated in 2004, which
increased steadily to 7.2 per 100 000 per year in 2008,
crossing the limit of 6.0 per 100 000 per year in 2006.
Discussion
In this study, the recently developed European defini-
tion for rare cancers was applied to the Netherlands. In
the Netherlands, 86% of the RARECARE-defined
entities and 17% (N≈14 000) of all newly diagnosed
cancers should be considered rare according to this
definition of a crude incidence rate of less than six cases
per 10 000 per year. For the 5-year period 2004–2008,
over 71 000 newly diagnosed rare cancers were observed.
Under the assumption that there would be an even dis-
tribution over all hospitals, a crude incidence of six per
100 000 per year would account for a maximum of 11
newly diagnosed patients with a specific type of rare
cancer per hospital per year or 1000 incident cases per
year in the Netherlands on the basis of 16.7 million
inhabitants and over 90 hospitals. Furthermore, these
patients would probably be diagnosed and treated by
different clinicians in each hospital. Of course, this
assumption does not reflect daily practice. Some patients
will be referred to, for instance, university hospitals,
resulting in even fewer or no patients per year in a gen-
eral hospital.
The percentage of rare cancer types among all cancer
diagnoses was similar to the RARECARE findings (about
17%) and was divided over a similar number of entities.
We observed fluctuations of almost one per 100 000 per
year in crude rates over the years. This may have con-
sequences for the entities with a crude rate around six per
100 000 person years. These entities could be classified
as rare one year and as nonrare the next year. We suggest
using the average incidence rate over 5 years to limit
random fluctuations affecting the classification as rare
cancer or not. An example in our results is oesophageal
388 European Journal of Cancer Prevention 2018, Vol 27 No 4
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adenocarcinoma, which would be classified as rare in
2004 (not shown), but would be considered not rare in
the following years because of increasing incidence. A
European study also observed increasing incidence rates
for oesophageal adenocarcinoma (Bosetti et al., 2008).
Some sex-related cancers, such as ‘Tumours of the testis
and paratestis’ and ‘Squamous cell of the cervix uteri’,
were classified as nonrare in the Netherlands, but as rare
in the RARECARE data set. This difference is the result
of different methods used to calculate the crude inci-
dence rate. In the RARECARE project, the total popu-
lation without differentiating for sex was used, whereas in
our study, we only used the population at risk for the sex-
related tumours, which results in higher incidence rates.
This same effect is detectable in all sex-related tumours,
but does not result in differences in classification. Owing
to the definition of the incidence rate, we suggest use of
the sex-specific population at risk. However, we do agree
that the limit should then also be changed to 12 per
100 000 for sex-specific cancers and that this limits the
applicability of the new definition.
Four entities were not rare in Europe but rare in the
Netherlands or vice versa. One of those entities concerns
‘Epithelial tumours of the hypopharynx and larynx’. This
difference was mainly because of the second-layer group
‘Squamous cell carcinoma and variants of the larynx’, and
not ‘Squamous cell carcinoma of the hypopharynx’. The
remaining difference was found at the first-layer level,
which includes unspecified and not otherwise specified
codes. Because some cancers are classified as not other-
wise specified, we expect an underestimation for the
incidence rates in the second-layer entities. We observed
this clearly in the data for ‘Epithelial tumours of the
pancreas’, where a nonrare first layer crude incidence of
10.4 per 100 000 per year was observed, whereas the sum
of all rare second-layer crude incidences equalled only
6.4 per 100 000 per year. This phenomenon was also
observed within European RARECARE data, and will
affect cancers that are mainly diagnosed clinically (with-
out pathological confirmation) more strongly. The
RARECARE project also reports this effect for the epi-
thelial tumours of the oesophagus. Our findings suggest a
better classification in the NCR because the sum of the
incidence rates of all second-layer entities comes close to
the incidence rate for the first nonrare layer entity. This
indicates a more detailed pathologic diagnostic workup
and coding in the Netherlands compared with overall
RARECARE data. Differences in outcome between
RARECARE and NCR data may partly be explained by
the inclusion of different incidence years (1995–2002 for
RARECARE and 2004–2008 for the Netherlands).
Because tumour classification evolves continuously
because of improved knowledge and better techniques, a
yearly update of the analyses carried out by the
RARECARE project, on the basis of the average for the
most recent five incidence years for which data are
available, should be carried out to provide an overview
and monitor the current situation of rare cancers in
Europe. To determine the differences in rare cancer
between countries, we propose that each country develop
a national list of rare cancers. Country-specific incidence
rates would also provide insight into the experience level
of countries with specific cancer entities. This knowledge
may subsequently lead to further clinical and/or scientific
collaboration.
Diagnosing and registering rare cancers, however, will
always be more difficult than diagnosing and registering
nonrare cancers because rare cancers (by definition) are
encountered less regularly. Therefore, misclassifications
may have occurred. Within the RARECARE project, a
data quality check was carried out, which covered the
years 1995–2002 and included three Dutch Cancer
Registries, covering 44.5% of the total population of the
Netherlands. These results were published on the
RARECARE website; http://www.rarecare.eu. In sum-
mary, the quality check for the Netherlands included a
review of 1018 cancers using the original patient files.
Overall, for all cases reviewed, the majority was found to
be registered correctly. For the selection of Dutch Cancer
Registries, a percentage ranging from 4.1 to 5.3 unspe-
cified morphology cases was found, which was one of the
Table 3 Number of rare and all tumours for the years 2004–2008
2004–2008
2004 2005 2006 2007 2008 Total Average per year
N of rare tumours 13 421 13 980 14 218 14 668 15 108 71 395 14 279
N of all tumoursa 80 616 81 632 84 119 86 800 89 228 422 395 84 479
Rare tumours (%) 16.6 17.1 16.9 16.9 16.9 16.9 16.9
aSource Netherlands Cancer Registry, available at: http://www.cijfersoverkanker.nl.
Table 4 Incidence per year on actual number of tumours for
2004–2008 and number of entities included
N per year
Percentage
of all rare
Percentage
of all tumours
N of
entities
Percentage
of N entities
≤0.5 881 6.2 1.0 85 33
>0.5<1.0 816 5.7 1.0 25 9.6
≥1.0<2.0 1607 11 1.9 21 8.1
≥2.0<3.0 3865 27 4.6 28 11
≥3.0<4.0 2904 20 3.4 26 10
≥4.0<5.0 755 5.3 0.9 9 3.5
≥5.0<6.0 3451 24 4.1 29 11
Total 14 279 100.0 16.9 223 85.8
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lowest percentages for the participating Cancer
Registries.
In conclusion, some improvements to the definition of
rare cancers could be made. First, by determining the
cut-off on the basis of an average annual rate of less than
six per 100 000 over 5 years instead of 1 year, the influ-
ence of fluctuations on the classification can be obviated.
Second, a sex-specific incidence limit should be
introduced.
In the Netherlands, almost one in six cancer patients is
affected by a cancer that is considered to be rare. Many of
these rare tumour entities were very rare, with an inci-
dence rate below 0.5, equalling ∼ 100 cases per year, in
the Netherlands, indicating the challenge that faces
clinicians confronted with a patient with such a rare
cancer. This also shows the need for (inter)national
cooperation in caring for these patients. Furthermore,
exploration of diagnostic, treatment and outcome, and
referral patterns is needed and may help to identify
caveats to research, which can help to enhance the care
for patients with rare cancers.
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